Day One (DAWN) Climbs to 3-Year High on $2.5-Billion Merger

Core Viewpoint - Day One Biopharmaceuticals Inc. is set to merge with France-based Servier for $2.5 billion, leading to a significant increase in its stock price, marking it as a stock to watch [1][2]. Group 1: Merger Details - Day One Biopharmaceuticals and Servier have entered into a definitive agreement for the acquisition, with Servier set to acquire shares at $21.50 each, representing a 68% increase from Day One's latest closing price [2]. - Following the announcement, Day One's shares peaked at $21.23 during intra-day trading, ultimately closing up by 65.88% at $21.20 [4]. Group 2: Strategic Implications - The merger is expected to close in the second quarter of the year, pending customary closing conditions [4]. - Day One's CEO, Jeremy Bender, emphasized that Servier's expertise in rare cancers and commitment to targeted therapies aligns with Day One's mission to provide medicines for patients with life-threatening diseases [4]. - Bender also noted that joining Servier offers an opportunity to enhance the reach of their science, particularly in pediatric low-grade glioma, while maintaining a patient-first approach [5].